This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

33/100

✓ Peer-reviewed alzhub usefulness score 33 out of 100. Risk genes beyond APOE

Topic: Brain proteins, microglia and lab models

MTX46943-mediated TREM2 activation leads to TREM2/DAP12 receptor complex formation and stabilizes surface location required for downstream signaling and microglia activation. These effects are differentiated from TREM2 agonistic antibodies and are required for downstream microglial activation. In vivo, human TREM2 is expressed by pathology-associated microglia and induced by amyloid plaques. Chronic, systemic treatment with MTX46943 leads to re-programming of microglia in the presence of amyloid pathology which in turn leads to reduction of neurotoxic amyloid beta species. Effects were observed at compound exposure levels in the brain consistent with MTX46943 in vitro potency. Muna Therapeutics is advancing MTX46943, a selective, potent, safe and brain exposed small molecule TREM2 agonist into clinical studies for the treatment of early AD. We demonstrate here key differentiated aspects of the mechanism by which MTX46943 targets TREM2 and induces microglial re-programming via receptor complex formation and stabilization. Chronic treatment of MTX46943 robustly and significantly reduces brain amyloid pathology at doses shown to promote peripheral and central biomarker responses. The present studies collectively support the best-in-class therapeutic potential of MTX46943 for the treatment of Alzheimer´s disease.

Key findings

MTX46943-mediated TREM2 activation leads to TREM2/DAP12 receptor complex formation and stabilizes surface location required for downstream signaling and microglia activation.
These effects are differentiated from TREM2 agonistic antibodies and are required for downstream microglial activation.
In vivo, human TREM2 is expressed by pathology-associated microglia and induced by amyloid plaques.
Chronic, systemic treatment with MTX46943 leads to re-programming of microglia in the presence of amyloid pathology which in turn leads to reduction of neurotoxic amyloid beta species.
Effects were observed at compound exposure levels in the brain consistent with MTX46943 in vitro potency.

Why it matters

This study reports that the small molecule TREM2 agonist MTX46943 activates microglia and, with chronic systemic treatment, reduces brain amyloid pathology in vivo. The company is advancing MTX46943 into clinical studies for early Alzheimer's, so this remains a preclinical compound that has not yet been shown to treat or prevent the disease in patients.

New to this subject? Start with our plain-English guide: Genetics →

Study details

Evidence strengthLow

How this study scored 33/100

Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomised / blinded because the record does not state it. We have no data on institution's track record, so that was left out: it earned 32 of the 97 points we could judge it on, which is 33 out of 100.

Component	Points	Why
Journal tier	7 / 10	Tier 3 — peer-reviewed journal (Alzheimer s & Dementia)
Journal's citation record	2 / 4	Alzheimer s & Dementia: journal h-index 228 (OpenAlex, 2026-10-29)
Study design	0 / 12	No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence	1 / 5	Rated “low” in our summary
Peer-review validation	10 / 10	Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent	4 / 5	2025 — within 3 year(s) of the newest study here
Sample size	0 / 4	Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported	0 / 3	No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people	0 / 3	Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomised / blinded	0 / 2	No randomisation or blinding stated — scores zero (not stated in the record — scored 0)
Times cited	1 / 7	Cited 1 times (OpenAlex, 2026-10-10)
Citations per year	0 / 5	0.3 citations a year over 3 year(s) since 2025
Impact for its field and year	1 / 6	Cited 0.3× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here	0 / 6	No other study in this library cites it
Still being cited	0 / 4	Cited 1 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record	2 / 4	Last-listed author Niels Plath: h-index 30 (OpenAlex, whole career)
Institution's track record	— / 3	No institution listed in OpenAlex — left out of this score
Multi-centre collaboration	0 / 3	OpenAlex lists 0 institution(s) in 0 countries — scores zero (affiliation lists can be incomplete)
Indexed in PubMed	2 / 2	Indexed in PubMed (PMID 41447159)
Free to read	2 / 2	Free to read
Points	32 / 97	Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 32 of the 97 points we could judge it on is 33 out of 100.
Total	33 / 100	—

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

APA 7th

Polydoro, M., Geric, I., Zheng, J., Bisgaard, T. S., Comer, A. L., Sans, L., et al. (2025). A Novel TREM2 Small Molecule Agonist MTX46943 Re‐Programs Human Microglia and Reduces Amyloid Pathology In Vivo. Alzheimer s & Dementia. https://doi.org/10.1002/alz70859_100777

Vancouver

Polydoro M, Geric I, Zheng J, Bisgaard TS, Comer AL, Sans L, et al. A Novel TREM2 Small Molecule Agonist MTX46943 Re‐Programs Human Microglia and Reduces Amyloid Pathology In Vivo. Alzheimer s & Dementia. 2025. doi:10.1002/alz70859_100777. PMID: 41447159.

BibTeX

@article{polydoro2025-41447159,
  author  = {Polydoro, Manuela and Geric, Ivana and Zheng, Jin and Bisgaard, Tina Sommer and Comer, Ashley L. and Sans, Laura and Lu, Ashley and Vilstrup, Joachim and others},
  title   = {{A Novel TREM2 Small Molecule Agonist MTX46943 Re‐Programs Human Microglia and Reduces Amyloid Pathology In Vivo}},
  journal = {Alzheimer s \& Dementia},
  year    = {2025},
  doi     = {10.1002/alz70859_100777},
  pmid    = {41447159},
  url     = {https://doi.org/10.1002/alz70859_100777}
}

Related studies in Risk genes beyond APOE

Also tagged “macrophages”

363 studies in the library carry the topic tag “macrophages”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 363 tagged studies.

Similar studies

More on Risk genes beyond APOE

See all studies in Risk genes beyond APOE →